Heart Attack

Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without...

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg...

HealthIQ Solutions and Eirion.ai Form Strategic Technology Innovation Partnership to Pioneer Predictive AI in Remote Care Management

Collaboration aims to deliver advanced clinical risk forecasting for life-threatening conditions, empowering physicians to intervene before adverse events occur.ROSWELL, Ga.,...

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034Enalapril is a widely prescribed ACE inhibitor used to treat...

New Pharmacoeconomic Analysis Finds KYZATREX® Could Cut the VA’s Total Cost of Testosterone Care by Nearly Half for America’s Veterans

Model projects up to $16.2 million in potential annual savings for every 50,000 veterans transitioned from office-administered injectable therapy —...

Caristo Diagnostics Expands Executive Team, Naming David Vort Chief Commercial Officer and Chris Louk Chief Financial Officer

Appointments to scale adoption of Caristo's AI-powered cardiovascular technologies globallyOXFORD, England and STAMFORD, Conn., July 23, 2026 /PRNewswire/ -- Caristo...

error: Content is protected !!